US Patent Issued to BeOne Medicines | on Sept. 15 for "(R) and (S)-3-(tert-butyl)-N-(1-(4-(6-(6-(4-((1-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-YL)phenyl)piperidin-4-YL)methyl)piperazin-1-YL)pyridin-3-YL)-7H-pyrrolo[2,3-dpyrimidin-4-YL)-2-methylphenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide as bruton's tyrosine kinase (BTK) degraders" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,735,423, issued on Sept. 15, was assigned to BeOne Medicines | GmbH (Basel, Switzerland).

"(R) and (S)-3-(tert-butyl)-N-(1-(4-(6-(6-(4-((1-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-YL)phenyl)piperidin-4-YL)methyl)piperazin-1-YL)pyridin-3-YL)-7H-pyrrolo[2,3-dpyrimidin-4-YL)-2-methylphenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide as bruton's tyrosine kinase (BTK) degraders" was invented by Hexiang Wang (Beijing), Bailin Lei (Beijing), Changxin Huo (Beijing), Dongqing Sun (Beijing), Jie Chen (Beijing), Zhiwei Wang (Beijing), Yucheng Wang (Beijing) and Huaqing Liu (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "(R) and (S)-3-(tert-butyl)-N-(1-(4-(6-(6-(4...